

May 1, 2026

To Listing Department, <b>NATIONAL STOCK EXCHANGE OF INDIA LIMITED</b> Exchange Plaza, Bandra Kurla Complex, Bandra (E), <b>MUMBAI -400 051</b>  <b>Company Code No. AUROPHARMA</b>	To The Corporate Relations Department <b>BSE LIMITED</b> Phiroz Jeejeebhoy Towers, 25 <sup>th</sup> floor, Dalal Street, <b>MUMBAI -400 001</b>  <b>Company Code No. 524804</b>
---	---

Dear Sir / Madam,

**Sub: CuraTeQ Biologics Secures Health Canada NOC for Bevqolva™ Bevacizumab Biosimilar**

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that:

CuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo Pharma Ltd, today announced it has received Notice of Compliance (NOC) from Health Canada's Biologics and Radiopharmaceutical Drugs Directorate (BRDD) for Bevqolva™, its bevacizumab biosimilar. Health Canada issues an NOC after a successful review, granting formal marketing authorization to the biosimilar by confirming it meets regulatory standards for safety, efficacy, and quality - comparable to the reference biologic drug under the Food and Drug Regulations.

Bevacizumab, a humanized monoclonal antibody, inhibits angiogenesis - the formation of new blood vessels - by blocking vascular endothelial growth factor A (VEGF-A). This action slows tumor vascular growth and treats multiple cancers, including colorectal and lung. Available in 100 mg and 400 mg formulations, the originator product Avastin is marketed by Roche/Genentech.

In 2025, Bevqolva™ secured marketing authorization from the MHRA and launched commercially for patients across the UK. The product is currently under review by the CHMP with the European Medicines Agency. CuraTeQ Biologics also has two additional biosimilar applications under review by Health Canada.

Please take the above information on record.

Yours faithfully,

**For AUROBINDO PHARMA LIMITED**

**B. Adi Reddy**  
**Company Secretary**

**AUROBINDO PHARMA LIMITED**

[www.aurobindo.com](http://www.aurobindo.com)

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.  
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833  
Email: [info@aurobindo.com](mailto:info@aurobindo.com) Website: [www.aurobindo.com](http://www.aurobindo.com)